ViroCell names Susan Nichols as CBO

ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).

The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

The appointment of Ms Nichols as CBO is a significant milestone in ViroCell’s continuing operational development as the company aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

Ms Nichols has a distinguished track record as an executive and business development professional and currently sits on the board of directors of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. She is also co-chair of its accelerator committee and co-chair of ARM’s Women’s Executive Forum.

Most recently, Ms Nichols was an executive officer at Propel BioSciences, a life sciences consultancy, supporting the business development and funding needs of early-stage biotech and pharmaceutical companies. Prior to that, she was chief executive of Falcon Therapeutics, an early-stage gene modified cell therapy company focused on solid tumors.